Publications by authors named "Diana Romana Chirovsky"
J Natl Cancer Inst
February 2021
Article Synopsis
- Head and neck squamous cell carcinoma (HNSCC) significantly impacts patients' quality of life, and the KEYNOTE-040 trial compared the effects of pembrolizumab to standard treatments in patients with recurrent HNSCC.
- In the study, 469 patients were assessed for health-related quality of life (HRQoL) using various questionnaires, revealing that those on pembrolizumab experienced a longer median time to deteriorating global health status compared to those on standard care.
- Results indicated that while the HRQoL scores remained stable for the pembrolizumab group at week 15, they declined for the standard of care group, highlighting pembrolizumab's potential as a more beneficial treatment option for improving quality
